All In Biotech

Drug Trial Radar · NCT03622580

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 940 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

940

Actual

Start

Sep 5, 2018

Primary completion

Oct 20, 2020

Study completion Sep 3, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • AfliberceptDrug

    Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

  • FaricimabDrug

    Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

  • Sham ProcedureProcedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive PopulationsTime frame: From Baseline through Week 56

Locations

185 sites in 16 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Retina Associates Southwest PC

    Tucson, Arizona

  • Retinal Diagnostic Center

    Campbell, California

  • Eye Medical Center

    Fresno, California

  • East Bay Retina Consultants

    Oakland, California

  • Southern CA Desert Retina Cons

    Palm Desert, California

  • California Eye Specialists Medical group Inc.

    Pasadena, California

  • Retina Consultants, San Diego

    Poway, California

  • Retina Consultants of Southern California

    Redlands, California

  • Kaiser Permanente Riverside Medical Center

    Riverside, California

  • University of California, Davis, Eye Center

    Sacramento, California

  • W Coast Retina Med Group Inc

    San Francisco, California

  • Orange County Retina Med Group

    Santa Ana, California

  • Colorado Retina Associates, PC

    Lakewood, Colorado

  • Rand Eye

    Deerfield Beach, Florida

  • Retina Care Specialists

    Palm Beach Gardens, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida

  • Retina Associates of Florida, LLC

    Tampa, Florida

  • University of South Florida

    Tampa, Florida

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Midwest Eye Institute

    Indianapolis, Indiana

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Retina Associates

    Lenexa, Kansas

  • Vitreo-Retinal Consultants

    Wichita, Kansas

  • Retina Associates of Kentucky

    Lexington, Kentucky

  • Paducah Retinal Center

    Paducah, Kentucky

  • Maine Eye Center

    Portland, Maine

  • The Retina Care Center

    Baltimore, Maryland

  • Johns Hopkins Med; Wilmer Eye Inst

    Baltimore, Maryland

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Beetham Eye Institute, Joslin Diabetes Center

    Boston, Massachusetts

  • Vitreo-Retinal Associates, PC

    Worcester, Massachusetts

  • Foundation for Vision Research

    Grand Rapids, Michigan

  • Assoc Retinal Consultants PC

    Royal Oak, Michigan

  • Associated Retinal Consultants, P.C.

    Traverse City, Michigan

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.